Agency for Science, Technology and Research

Cti Biopharma Corp.

S'bio Pte Ltd

H. Lundbeck A/s

The Brigham and Women's Hospital, Inc.

National University of Singapore

Cell Therapeutics, Inc.

Harish Kumar Mysore Nagaraj

Cheng Hsia Angeline Lee

Stephanie Blanchard

Eric T. Sun

Yee Ling Evelyn Tan

Anders Poulsen

Anthony Deodaunia William

Eric T Sun

Stephanie Eliane Blanchard

Jan Kehler

Ee Ling Teo

Soo Yei Ho

Kantharaj Ethirajulu

Thomas Ruhland

Wei Ling Wang

Athisayamani Jeyaraj Duraiswamy

Jenefer Alam

Thomas Hugo Keller

Morten Bang Norgaard

Li Chai

Morten Bang Nørgaard

Cheng San Brian Chia

Søren Møller Nielsen

Shi Hua Ang

Friedrich Kroll

Daniel Geoffrey Tenen

Bee Hui Liu

Sum Wai Eldwin Tan

Berith Bjornholm

Cheng Hsia Angelina Lee

Berith Bjørnholm

Tore Hansen

Stéphanie Blanchard

Cheng Hsia Lee

Harish Kumar Nagaraj

Yee Ling Tan

Berith Bjoernholm

Soeren Moeller Nielsen

Morten Bang Noergaard

The present invention relates to compounds of general Formula (I), and/or tautomers, enantiomers, solvates, hydrates, and pharmaceutically acceptable salts thereof. The present invention also relates to compounds of Formula (I) for use in therapy, methods of treating isoprenylcysteine carboxyl methyltransferase (ICMT) related disorders or uses of compounds of Formula (I) in the manufacture of a medicament for the treatment of ICMT-related disorders, wherein the disorder is cancer and/or progeria. The present invention further relates to processes for synthesizing compounds of Formula (I).

Compounds useful as inhibitors of isoprenylcysteine carboxyl methyltransferase

The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.

Oxygen linked pyrimidine derivatives

Isolated peptides and pharmaceutical compositions comprising isolated peptides that bind to retinoblastoma binding protein 4 (RBBp4) and block the Spalt-Like Transcription Factor 4 (SALL4)-RBBp4 interaction are described. Methods of inhibiting binding of SALL4 to RBBp4 and methods of treating a subject having a disorder mediated by a dysregulation of SALL4 are also described.

Therapeutic spalt-like transcription factor 4 (SALL4) peptide

The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein Rrepresents optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from Calkoxy); optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C-6alkyl, Calkoxy, Chaloalkyl, Chaloalkoxy and halo); or -alkylaryl; Rrepresents H; or alkyl; Rrepresents H; or alkyl; U, V and W represent &#x2014;(CH)&#x2014;; or U and V together represent &#x2014;CH&#x2550;CH&#x2014; and W represents C&#x2550;O; Y represents aryl; heteroaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from Calkyl, Calkoxy, Chaloalkyl, Chaloalkoxy and halo); or optionally substituted heterocyclyl (wherein optional substituents include one or more substituents each independently selected from Calkyl, Calkoxy, &#x2014;C(O)OCalkyl, &#x2014;C(O)Calkyl and &#x2014;C(O)NHCalkyl); and Z represents aryl; heteroaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from Calkyl, Calkoxy, Chaloalkyl, Chaloalkoxy and halo); or optionally substituted heterocyclyl (wherein optional substituents include one or more substituents each independently selected from Calkyl, Calkoxy, &#x2014;C(O)OCalkyl, &#x2014;C(O)Calkyl and &#x2014;C(O)NHCalkyl). 

Maleimide derivatives as modulators of wnt pathway

The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumors and cancers as well as other disorders or conditions related to or associated with kinases.

The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to heteroalkyl linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumors and cancers as well as other conditions or disorders associated with kinases.

Heteroalkyl linked pyrimidine derivatives

The present invention relates to cyclopropyl derivatives of formula (I) and salt thereof. These compounds are NK3 receptor antagonists and may therefore be useful for treatment of diseases where the NK3 receptor is implicated, e.g. psychotic disorders. 

Cyclopropyl derivatives as NK3 receptor antagonists

The present invention relates to novel compounds of formula I wherein the variable groups are as defined in the claims or a pharmaceutically acceptable acid addition salt thereof. The compounds of the invention are NK2 antagonists. 

3,4-dihydro-1H-isoquinolin-2-yl-derivatives

Growing community of inventors

Singapore, Singapore

Anders Poulsen